TRM - 359 (etoricoxib) is being developed as a breakthrough, first approved treatment for a serious pediatric orphan disease for which high-potency opioid therapies are the only available therapies.
In discussions with FDA regarding the proposed clinical development plan for TRM - 359
Targeting pediatric population to avoid opioid exposure in young patients
Preparing to file multiple orphan designations
Anticipating fast-track or break-through therapy status
Additional follow-on indications are being explored